Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Squamous Non-Small Cell Lung Cancer.

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Esophageal Cancer.

Daiichi Sankyo (OTCPK:DSKYF) stock slid 10% Friday after the Japanese drugmaker announced it had received approval in Japan ...

Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data ...

Treatment for lung cancer varies according to age, type of cancer, extent of disease, tolerance to medication and patient preference. Treatment options include a combination of surgery, radiation, ...

The Switch has been an enormous success — it’s the third-best-selling console of all time, behind only the PlayStation 2 and Nintendo’s own DS handheld — which presents both a big ...

这一突破性疗法认定基于全球性2期临床试验TROPiCS-03中ES-SCLC ... for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer. Retrieved December 18, 2024, from https ...

Dec. 5, 2024 — Improvements in cancer prevention and screening have averted more deaths from five cancer types combined over the past 45 years than treatment advances, according to a modeling study.

We review the major Switch 2 rumors and leaked images, including an 8-inch display, magnetic Joy-Cons, system dimensions, and a potential release date. I’ve been PCMag’s home entertainment ...

Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab ...